Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Arecor Therapeutics PLC (6UI) AI Stock Analysis

DE:6UI

Arecor Therapeutics PLC

(Frankfurt:6UI)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Very Low LeverageA very lightly levered balance sheet gives Arecor greater financial flexibility than a highly indebted development-stage biotech. Low debt reduces interest and refinancing pressure, allowing more of its resources to support research, partnerships, and commercialization over the next several quarters.
Negative Factors
Sharp Revenue DeclineThe sharp 2025 revenue contraction shows that Arecor’s commercial and partnered income is volatile rather than steadily compounding. Such variability can make planning and investment in development programs more difficult, while weakening confidence in the durability of the current revenue base.

Arecor Therapeutics PLC (6UI) vs. iShares MSCI Germany ETF (EWG)

-20%0%20%40%60%80%DE:6UI+60.19%EWG+5.59%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
EUR 37.37M
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
165.0
Beta (1Y)
-0.10
Revenue Growth
―
EPS Growth
―
Country
Germany
Employees
33
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Arecor Therapeutics PLC Business Overview & Revenue Model

Company Description

Arecor Therapeutics PLC is a biopharmaceutical enterprise dedicated to creating therapies for diabetes and various other medical conditions. The company utilizes its exclusive Arestat formulation technology platform to both cultivate its own range of...

Arecor Therapeutics PLC Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:6UI against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
GB:BVXPGB:BVXP89OutperformGBP 104.50M14.1467.81%7.32%-1.10%0.32%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
GB:FABGB:FAB49NeutralGBP 7.51M-6.06-97.87%―7.38%44.13%
GB:AVCTGB:AVCT43NeutralGBP 294.51M-6.44-1293.07%―――
GB:OXBGB:OXB43NeutralGBP 652.29M-15.39-54.51%―15.97%3.72%
GB:APTAGB:APTA37UnderperformGBP 10.23M-9.50-46.61%―28.35%57.14%

* Healthcare Sector Average

Performance Comparison

-50%0%50%DE:6UIGB:AVCTGB:BVXPGB:OXBGB:FABGB:APTADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
DE:6UI and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:6UIArecor Therapeutics PLC0.860.3155.86%
GB:AVCTAvacta Group plc58.70-13.20-18.36%
GB:BVXPBioventix plc2050.009.150.45%
GB:OXBOxford Biomedica (otc)532.00-128.00-19.39%
GB:FABFusion Antibodies Plc6.00-7.25-54.72%
GB:APTAAptamer Group Plc0.28-0.52-64.38%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.